Abstract: A method for the delivery of aggrecan precursors to the joint of a subject, comprising the steps of: a) applying a composition comprising one or more aggrecan precursors chosen from the list comprising hyaluronic acid, glucosamine sulfate and/or chondroitin sulfate to the skin of the subject on or near a joint, wherein the composition is applied between the skin and a flexible magnetic film.

Abstract: A method for the delivery of aggrecan precursors to the joint of a subject, comprising the steps of: a) applying a composition comprising one or more aggrecan precursors chosen from the list comprising hyaluronic acid, glucosamine sulfate and/or chondroitin sulfate to the skin of the subject on or near a joint, wherein the composition is applied between the skin and a flexible magnetic film.

Abstract: A method for the delivery of a skin care active agent comprising the following step: applying an active agent(s) between a target dermal barrier and a magnetic device comprising one or more pairs of displaced dipolar magnetic elements linked by a magnetic return wherein the magnetic return is orientated on the surfaces of the dipole pair distal to the dermal barrier.

Abstract: A method for programming a transdermal delivery device arranged to deliver a composition to a user, comprising the steps of receiving at least one variable parameter regarding a transdermal delivery method, utilising an algorithm to derive at least one control instruction for a transdermal delivery device utilising the at least one variable parameter, and providing the at least one instruction to the transdermal delivery device to effect the transdermal delivery method.

Abstract: A method for the delivery of an oral care active agent comprising the following step: applying an active agent(s) between a target oral biological barrier and a magnetic device comprising one or more pairs of displaced dipolar magnetic elements linked by a magnetic return wherein the magnetic return is orientated on the surfaces of the dipole pair distal to the biological barrier.

Abstract: The present invention relates to an agent having activity in the treatment of a tissue disruption.

Abstract: A device for delivery of a measured or predetermined dose of an active agent to a dermal or mucosal surface comprising: a) a deformable chamber comprising at least one dome-shaped member defining a reservoir for an active agent; and b) a porated disc.

Abstract: A device for delivering an active agent to a dermal or mucosal surface comprising: a) a first portion configured to define a delivery surface for presentation to a dermal or mucosal surface to deliver an active agent; and b) a second portion configured as a body to be held by a user further comprising a means for driving the passage of the active agent across the dermal or mucosal surface wherein the first portion and the second portion are adapted to be releasably interconnected and wherein the means for driving the passage of the active agent across the dermal or mucosal surface comprises an electromagnetophoresis dermaportation device located immediately adjacent the point of interconnection to the first portion.

Abstract: The present invention discloses a composition that contains (1) an effective amount of an analgesically and/or anti-inflammatory active fraction separated from a mixture of plasma and/or serum, and (2) at least one metal, metal ion or metal salt, in which the mixture has been denatured. Also disclosed are methods of producing the composition for treating a subject afflicted with inflammation and/or pain.

Abstract: A method for the delivery of a skin care active agent comprising the following step: applying an active agent(s) between a target dermal barrier and a magnetic device comprising one or more pairs of displaced dipolar magnetic elements linked by a magnetic return wherein the magnetic return is orientated on the surfaces of the dipole pair distal to the dermal barrier.

Abstract: A method for the delivery of an oral care active agent comprising the following step: applying an active agent(s) between a target oral biological barrier and a magnetic device comprising one or more pairs of displaced dipolar magnetic elements linked by a magnetic return wherein the magnetic return is orientated on the surfaces of the dipole pair distal to the biological barrier.

Abstract: The present invention discloses a composition that contains (1) an effective amount of an analgesically and/or anti-inflammatory active fraction separated from a mixture of plasma and/or serum, and (2) at least one metal, metal ion or metal salt, in which the mixture has been denatured. Also disclosed are methods of producing the composition for treating a subject afflicted with inflammation and/or pain.

Abstract: The present invention relates to an apparatus and method for improving the delivery of desirable substances across a membrane utilizing a varying electromagnetic energisation profile. More particularly, the invention provides methods for modifying the cellular environment of such membranes and the behaviour of substance molecules during transport across a membrane. In use, the profile will have application in, enhancing transmembrane delivery of substances (such as pharmaceuticals, nutraceuticals, biopharmaceuticals and cosmeceuticals), and/or enhancing or expanding a cellular cohort of membranes and surrounding tissues.

Abstract: An apparatus (40) is disclosed for facilitating transdermal delivery of therapeutic substances. The apparatus (40) comprises means (44) for producing an electromagnetic field, control means (26, 34) arranged to control said field producing means to alternately produce active and substantially inactive electromagnetic field portions. Each active electromagnetic field portion includes an electromagnetic field packet having a plurality of successive electromagnetic field pulses, and each substantially inactive electromagnetic field portion includes no electromagnetic field pulses. During use, when the electromagnetic field is incident on a patient, dermal permeability is increased. A corresponding method is also disclosed.

Abstract: The present invention relates to a method and apparatus for enhanced transdermal diffusion of substances (such as pharmaceuticals, nutraceuticals, biopharmaceuticals and cosmeceutical) by application of anisotropic magnetic fields having distinctive, complex characteristics.

Abstract: The present invention discloses a composition that contains (1) an effective amount of an analgesically and/or anti-inflammatory active fraction separated from a mixture of plasma and/or serum, and (2) at least one metal, metal ion or metal salt, in which the mixture has been denatured. Also disclosed are methods of producing the composition for treating a subject afflicted with inflammation and/or pain.

Abstract: The invention relates to an agent having cytokine mediating activity. In particular the invention relates to a composition comprising a fraction of denatured plasma proteins and at least one metal, metal ion or metal salt thereof, wherein said mixture has cytokine mediating activity.

Abstract: The present invention discloses a composition that contains (1) an effective amount of an analgesically and/or anti-inflammatory active fraction separated from a mixture of plasma and/or serum, and (2) at least one metal, metal ion or metal salt, in which the mixture has been denatured. Also disclosed are methods of producing the composition for treating a subject afflicted with inflammation and/or pain.

Abstract: In order to facilitate the capture of the three-dimensional anatomical measurements the present invention provides a self-adhesive label (10) having a plurality of visual markers providing thereon. The label (10) is sufficiently flexible to conform to a contour of an anatomical region to which it is adhered. The self-adhesive label is “T-shaped” and includes a first horizontal segment (12) having a series of evenly spaced, dark bands 14 separated by light spaces printed thereon. The label (10) may be manufactured from paper or a suitable plastics material and in this case is designed to be adhered to the lower or upper leg region of a patient with the first segment (12) wrapped partly around the leg so as to adopt the contours of the leg region.

Abstract: Acid whey, the by-product from the manufacture of fresh cheeses such as cottage cheese, is clarified, filtered and subjected to lactose hydrolysis, splitting the lactose disaccharide into the monosaccharides glucose and galactose. The liquid is sterilized and cultured with Baker's yeast and used as a growth medium for that yeast. After yeast growth is substantially completed the yeast solids are separated and the liquid remaining is discharged into waste-water receiving systems, the liquid significantly reduced in organic waste loading as compared to untreated acid wheys.